This Article Full Text Full Text (PDF) All Versions of this Article: 42/4/844    most recent 01.HYP.0000085332.69777.D1v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mendez, M. Articles by LaPointe, M. C. Search for Related Content PubMed PubMed Citation Articles by Mendez, M. Articles by LaPointe, M. C. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Related Collections Cell signalling/signal transduction Other hypertension Gene expression Gene regulation Growth factors/cytokines Hypertrophy

(Hypertension. 2003;42:844.)
© 2003 American Heart Association, Inc.

Scientific Contributions

PPAR Inhibition of Cyclooxygenase-2, PGE₂ Synthase, and Inducible Nitric Oxide Synthase in Cardiac Myocytes

From the Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Mich.

Correspondence to Margot C. LaPointe, PhD, Hypertension and Vascular Research Division, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI 48202-2689. E-mail mclapointe{at}aol.com

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear receptor superfamily. They regulate lipid metabolism, glucose homeostasis, cell proliferation, and differentiation and modulate inflammatory responses. We examined whether PPAR is functional in cultured neonatal ventricular myocytes and studied its role in inflammation. Western blots revealed PPAR in myocytes. When myocytes were transfected with a PPAR response element reporter plasmid (PPRE-TK-luciferase), the PPAR activator 15-deoxy-^12,14-prostaglandin J₂ (15dPGJ₂) increased promoter activity, whereas cotransfection of a dominant negative PPAR inhibited it. To determine the role of 15dPGJ₂ in expression of proinflammatory genes, we tested its effect on interleukin-1ß induction of cyclooxygenase-2 (COX-2). 15dPGJ₂ decreased interleukin-1ß stimulation of COX-2 by 40% and PGE₂ production by 73%. We next questioned whether 15dPGJ₂ was modulating the expression of inducible prostaglandin E₂ synthase (PGES) and found that it completely blocked interleukin-1ß induction of PGES. Use of a second PPAR agonist, troglitazone, and the selective PPAR antagonist GW9662 demonstrated that the effects seen were PPAR-dependent. In addition, we found that 15dPGJ₂ blocked interleukin-1ß stimulation of inducible nitric oxide synthase (iNOS). We concluded that 15dPGJ₂ may play an anti-inflammatory role in a PPAR-dependent manner, decreasing COX-2, PGES, and PGE₂ production, as well as iNOS expression.

Key Words: myocytes • nitric oxide synthase • cyclooxygenase • prostaglandins

This article has been cited by other articles:

				Y. Yuhas, E. Berent, R. Cohen, and S. Ashkenazi Roles of NF-{kappa}B Activation and Peroxisome Proliferator-Activated Receptor Gamma Inhibition in the Effect of Rifampin on Inducible Nitric Oxide Synthase Transcription in Human Lung Epithelial Cells Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1539 - 1545. [Abstract] [Full Text] [PDF]

				P. A. Konstantinopoulos, M. V. Karamouzis, and A. G. Papavassiliou Effect of Aspirin Use on Thiazolidinediones and Cardiovascular Events JAMA, April 2, 2008; 299(13): 1539 - 1539. [Full Text] [PDF]

				B. Samuelsson, R. Morgenstern, and P.-J. Jakobsson Membrane Prostaglandin E Synthase-1: A Novel Therapeutic Target Pharmacol. Rev., September 1, 2007; 59(3): 207 - 224. [Abstract] [Full Text] [PDF]

				Y. Fu, Z. Wang, W. L. Chen, P. K. Moore, and Y. Z. Zhu Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1545 - H1552. [Abstract] [Full Text] [PDF]

				B. N. Finck The PPAR regulatory system in cardiac physiology and disease Cardiovasc Res, January 15, 2007; 73(2): 269 - 277. [Abstract] [Full Text] [PDF]

				Y. Ye, Y. Lin, S. Atar, M.-H. Huang, J. R. Perez-Polo, B. F. Uretsky, and Y. Birnbaum Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1158 - H1169. [Abstract] [Full Text] [PDF]

				Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats FASEB J, June 1, 2006; 20(8): 1162 - 1175. [Abstract] [Full Text] [PDF]

				P Froment, F Gizard, D Defever, B Staels, J Dupont, and P Monget Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J. Endocrinol., May 1, 2006; 189(2): 199 - 209. [Abstract] [Full Text] [PDF]

				S Soumian, R Gibbs, A Davies, and C Albrecht mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease J. Clin. Pathol., December 1, 2005; 58(12): 1255 - 1260. [Abstract] [Full Text] [PDF]

				Y. Moon, W. C. Glasgow, and T. E. Eling Curcumin Suppresses Interleukin 1{beta}-Mediated Microsomal Prostaglandin E Synthase 1 by Altering Early Growth Response Gene 1 and Other Signaling Pathways J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 788 - 795. [Abstract] [Full Text] [PDF]

				E. B. E. Berry, J. A. Keelan, R. J. A. Helliwell, R. S. Gilmour, and M. D. Mitchell Nanomolar and Micromolar Effects of 15-Deoxy-{Delta}12,14-prostaglandin J2 on Amnion-Derived WISH Epithelial Cells: Differential Roles of Peroxisome Proliferator-Activated Receptors {gamma} and {delta} and Nuclear Factor {kappa}B Mol. Pharmacol., July 1, 2005; 68(1): 169 - 178. [Abstract] [Full Text] [PDF]

				Z. Gong, D. Xie, Z. Deng, R. M. Bostick, S. J. Muga, T. G. Hurley, and J. R. Hebert The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas Carcinogenesis, March 1, 2005; 26(3): 579 - 585. [Abstract] [Full Text] [PDF]

				T. Shimazu, I. Inoue, N. Araki, Y. Asano, M. Sawada, D. Furuya, H. Nagoya, and J. H. Greenberg A Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Reduces Infarct Size in Transient but Not in Permanent Ischemia Stroke, February 1, 2005; 36(2): 353 - 359. [Abstract] [Full Text] [PDF]

				F. J. Sanchez-Gomez, E. Cernuda-Morollon, K. Stamatakis, and D. Perez-Sala Protein Thiol Modification by 15-deoxy-{Delta}12,14-Prostaglandin J2 Addition in Mesangial Cells: Role in the Inhibition of Pro-inflammatory Genes Mol. Pharmacol., November 1, 2004; 66(5): 1349 - 1358. [Abstract] [Full Text] [PDF]